Ohio State Study Finds 27% Job Changes but Limited Financial Toxicity in Vestibular Schwannoma Patients
Updated
Updated · BIOENGINEER.ORG · Sep 13
Ohio State Study Finds 27% Job Changes but Limited Financial Toxicity in Vestibular Schwannoma Patients
1 articles · Updated · BIOENGINEER.ORG · Sep 13
Summary
A 41-patient Ohio State survey found vestibular schwannoma treatment often disrupted work, with 27% changing jobs and 41% reporting altered duties after management began.
Validated financial-toxicity measures still showed modest strain for most respondents: the median COST score was 32, while 10% reported moderate financial toxicity and 5% severe distress.
The study is among the first to apply patient-reported financial toxicity tools to this benign skull-base tumor, where treatment choices have usually been judged by hearing, balance and facial-nerve outcomes rather than household finances.
Researchers cautioned that the small, self-selected sample—drawn through the Acoustic Neuroma Association—limits how broadly the findings apply and cannot show how financial strain changes over time.
The authors said larger prospective studies are needed to identify which patients face the greatest economic risk as surgery, radiosurgery and observation remain shared treatment options.